KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Cash (2020 - 2025)

Aurinia Pharmaceuticals' Change in Cash history spans 6 years, with the latest figure at $7.0 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 84.83% year-over-year to $7.0 million; the TTM value through Dec 2025 reached -$3.2 million, down 109.32%, while the annual FY2025 figure was -$3.2 million, 109.32% down from the prior year.
  • Change in Cash reached $7.0 million in Q4 2025 per AUPH's latest filing, down from $20.2 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $174.3 million in Q4 2021 to a low of -$115.8 million in Q1 2021.
  • Average Change in Cash over 5 years is -$9.6 million, with a median of -$6.2 million recorded in 2023.
  • The largest YoY upside for Change in Cash was 1768.08% in 2024 against a maximum downside of 325.72% in 2024.
  • A 5-year view of Change in Cash shows it stood at $174.3 million in 2021, then tumbled by 95.34% to $8.1 million in 2022, then crashed by 69.48% to $2.5 million in 2023, then skyrocketed by 1768.08% to $46.3 million in 2024, then plummeted by 84.83% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Change in Cash are $7.0 million (Q4 2025), $20.2 million (Q3 2025), and -$13.4 million (Q2 2025).